Rec-Biotechnology
Dedicated to the R&D, production and commercialization of innovative vaccines, leveraging its core technology platforms.
Launch date
Employees
Market cap
-
Enterprise valuation
CAD1.5b (Public information from Jun 2021)
Taizhou Zhejiang (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$72.7m | Series A | ||
$227m | Series B | ||
$156m Valuation: $1.1b | Series C | ||
| Total Funding | CAD621m | ||